Synthesis, Characterization and Biological Evaluation of New Ru(II) Polypyridyl Photosensitizers for Photodynamic Therapy by Frei, Angelo et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Synthesis, Characterization and Biological Evaluation of New Ru(II)
Polypyridyl Photosensitizers for Photodynamic Therapy
Frei, Angelo; Rubbiani, Riccardo; Tubafard, Solmaz; Blacque, Olivier; Anstätt, Philipp; Felgenträger,
Ariane; Maisch, Tim; Spiccia, Leone; Gasser, Gilles
Abstract: Two Ru(II) polypyridyl complexes, Ru(DIP)2(bdt) (1) and [Ru(dqpCO2Me)(ptpy)](2+) (2)
(DIP = 4,7-diphenyl-1,10-phenanthroline, bdt = 1,2-benzenedithiolate, dqpCO2Me = 4-methylcarboxy-
2,6-di(quinolin-8-yl)pyridine), ptpy = 4’-phenyl-2,2’:6’,2￿-terpyridine) have been investigated as photo-
sensitizers (PSs) for photodynamic therapy (PDT). In our experimental settings, the phototoxicity and
phototoxic index (PI) of 2 (IC50(light): 25.3 ￿M, 420 nm, 6.95 J/cm(2); PI >4) and particularly of 1
(IC50(light): 0.62 ￿M, 420 nm, 6.95 J/cm(2); PI: 80) are considerably superior compared to the two
clinically approved PSs porfimer sodium and 5-aminolevulinic acid. Cellular uptake and distribution of
these complexes was investigated by confocal microscopy (1) and by inductively coupled plasma mass
spectrometry (1 and 2). Their phototoxicity was also determined against the Gram-(+) Staphylococcus
aureus and Gram-(-) Escherichia coli for potential antimicrobial PDT (aPDT) applications. Both com-
plexes showed significant aPDT activity (420 nm, 8 J/cm(2)) against Gram-(+) (S. aureus; >6 log10
CFU reduction) and, for 2, also against Gram-(-) E. coli (>4 log10 CFU reduction).
DOI: 10.1021/jm500566f
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-100438
Accepted Version
Originally published at:
Frei, Angelo; Rubbiani, Riccardo; Tubafard, Solmaz; Blacque, Olivier; Anstätt, Philipp; Felgenträger,
Ariane; Maisch, Tim; Spiccia, Leone; Gasser, Gilles (2014). Synthesis, Characterization and Biological
Evaluation of New Ru(II) Polypyridyl Photosensitizers for Photodynamic Therapy. Journal of Medicinal
Chemistry, 57(17):7280-7292. DOI: 10.1021/jm500566f
 1
Synthesis, Characterization and Biological 
Evaluation of New Ru(II) Polypyridyl 
Photosensitizers for Photodynamic Therapy 
Angelo Frei,a,† Riccardo Rubbiani,a,† Solmaz Tubafard,b Olivier Blacque,a Philipp Anstaett,a 
Ariane Felgenträger,c Tim Maisch,c Leone Spiccia,b and Gilles Gasser a,* 
[a] Department of Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, 
Switzerland; [b] ARC Centre of Excellence for Electromaterials Science and School of 
Chemistry, Monash University, Clayton, Victoria 3800, Australia; [c] Department of 
Dermatology, Regensburg University Hospital, D-93053 Regensburg, Germany. 
 
 2
ABSTRACT. 
Two Ru(II) polypyridyl complexes, Ru(DIP)2(bdt) (1) and [Ru(dqpCO2Me)(ptpy)]2+ (2) (DIP = 
4,7-diphenyl-1,10-phenanthroline; bdt = 1,2-benzenedithiolate; dqpCO2Me = 4-methylcarboxy-
2,6-di(quinolin-8-yl)pyridine); ptpy = 4’-phenyl-2,2’:6’,2’’-terpyridine) have been investigated 
as photosensitizers (PSs) for photodynamic therapy (PDT). In our experimental settings, the 
phototoxicity and photo-index (PI) of 2 (IC50(light): 25.3 μM, 420 nm, 6.95 J/cm2; PI: >4) and 
particularly of 1 (IC50(light): 0.62 μM, 420 nm, 6.95 J/cm2; PI: 80) are considerably superior 
compared to the two clinically approved PSs porfimer sodium and 5-aminolevulinic. Cellular 
uptake and distribution of these complexes was investigated by confocal microscopy (1) and by 
inductively coupled plasma-mass spectrometry (1 and 2). Their phototoxicity was also 
determined against the Gram-(+) S. aureus and Gram-(−) E. coli for potential antimicrobial PDT 
(aPDT) applications. Both complexes showed significant aPDT activity (420 nm, 8 J/cm2) 
against Gram-(+) (S. aureus; >6 log10 CFU reduction) and, for 2, also against Gram-(−) E. coli 
(>4 log10 CFU reduction).  
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Introduction. 
Cancer has arguably been one of the most studied disease in the last 100 years. Despite 
enormous research efforts, cancer has caused over eight million casualties or 13% of all deaths 
worldwide in 2012.1 The cornerstones of cancer therapy are radiotherapy, surgery and 
chemotherapy. In the search for better approaches, photodynamic therapy (PDT) has proven to 
be a promising new, effective and non-invasive chemotherapeutic treatment modality. The 
general concept of PDT is based on a photosensitizer (PS), an ideally non-toxic molecule with a 
higher affinity for cancer cells over healthy cells, that can be excited by irradiation with light and 
reach a triplet excited state through intersystem crossing. In this state, the PS can react with a 
substrate or solvent molecule (Type I reaction), through hydrogen atom or electron transfer, 
generating radicals. The PS can also transfer energy to molecular oxygen (Type II reaction), 
forming most prominently singlet oxygen (1O2).2, 3 The products of these two types of reactions 
are highly reactive and have been shown to cause severe cellular stress and to lead to apoptosis 
and/or necrosis.4-6 The advantages of PDT over other cancer therapies are the high 
spatiotemporal control and the low systemic toxicity of the treatment.7 Recently, PDT has also 
been investigated as a new remedy against bacterial infections.8 The application of antimicrobial 
PDT (aPDT) is intriguing because, unlike conventional antibiotics, aPDT does not have one 
specific target but instead affects multiple sites. This drastically decreases the incidence of 
resistance. In fact, resistance against aPDT has not been observed yet.9, 10 With the imminent 
threat of widespread antibiotic resistance, aPDT could be a much needed new approach to fight 
the rapidly emerging, multidrug resistant superbugs. Since the approval of the first PDT drug 
(porfimer sodium) in 1993, multiple (13 as of 2003) PDT PSs have reached the market.2 All of 
them are macrocyclic organic molecules, mostly porphyrin derivatives but also phtalocyanine- 
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and chlorin-based molecules.2 These PSs share several drawbacks such as a cumbersome 
synthesis and purification, poor water solubility and slow clearance leading to prolonged 
photosensitivity in patients.11, 12 There is therefore a need for novel PS with better photophysical 
and biological properties. The biological, chemical and photolytic stability are key properties of 
a PS for potential PDT applications. Additionally, the PS should also display a high phototoxic 
index (PI = ratio between toxicity in the dark and upon light irradiation), a high 1O2 production 
quantum yield as well as being active at red-NIR wavelengths to allow for a deeper tissue 
penetration.  
Ruthenium complexes have been under investigation for their anticancer activity for 
decades.13-18 They have gained widespread attention since two complexes, namely NAMI-A and 
KP1019 (and the respective sodium salt KP1339), passed early clinical trials.19-21  
The use of ruthenium in PDT however, has been quite limited so far. There have been multiple 
reports on porphyrin PSs decorated with ruthenium-based substituents. The resulting hybrid 
complexes exhibited significantly higher PIs than the individual moieties.22-27 Charlesworth,28 
Carneiro et al.29 also investigated organic PSs, phtalocyanines, conjugated to ruthenium 
moieties. Although the increased PIs are promising, this approach is not ideal as it requires an 
even longer synthetic pathway than the macrocyclic organic PSs alone. Following a similar 
approach, Zhou and co-workers coordinated hypocrellin B, an easily prepared phototoxic 
compound, to ruthenium. The resulting complex showed promising photosensitizing and 
photodamage properties in the red-NIR region superior to the hypocrellin B alone.30 Another 
branch in the research of light-activated ruthenium complexes has investigated the ability of such 
compounds to release ligands and/or undergo ligand exchanges upon light irradiation. For 
instance Zayat,31 Salierno and co-workers,32 have reported complexes that release biologically 
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active molecules upon light irradiation. On the other hand, Sun,33 Goldbach,34 Wachter,35 
Sgambellone et al.36 have described a series of ruthenium complexes which undergo ligand 
exchange and subsequent DNA binding or even cleavage upon irradiation at red-NIR 
wavelengths. The use of ruthenium complexes for 1O2 production has gained attention only in 
recent years. Notably, Lincoln et al. have reported ruthenium polypyridyl complexes that 
efficiently produce 1O2 upon irradiation with white light and exhibit high phototoxic indices in a 
metastatic melanoma model.37 These promising, but very limited reports indicate the enormous 
potential of ruthenium-based PS. Still, the hitherto reported ruthenium PSs are not ideal. The 
conjugation of ruthenium to porphyrins does not facilitate their already cumbersome synthesis. 
Moreover, nuclear DNA might not be optimal target in PDT since DNA damage causes 
mutagenesis, which can result in resistance to further treatments.38, 39 Hence, there certainly is 
still much uncharted chemical space for ruthenium PSs in PDT.  
By comparison, in the realm of antibacterial research, ruthenium complexes have only 
sparingly been studied. There have been some reports on mono- and polynuclear Ru(II) 
compounds that effectively reduce the viability of different bacterial strains.40-43 However, the 
field of aPDT is still in its infancy and, to our knowledge, no ruthenium PSs have been 
investigated for this purpose. This motivates further investigations into ruthenium complexes for 
antimicrobial applications. Recently, we have been applying Ru(II) polypyridyl complexes as 
PSs in PDT using low light doses at 350/420 nm. The studied complexes showed promising 
properties with regard to their 1O2 yields, cellular uptake and phototoxic index.44 Building on 
these promising preliminary results, we have embarked on a program to investigate in-depth the 
use of such complexes as PSs in PDT. Our aim is to develop biologically stable Ru(II)-based PSs 
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with a straight-forward synthesis and purification, high 1O2 production quantum yield, high PI 
and possibly alternative target sites. 
In the search for novel ruthenium PSs in PDT, we turned our attention to the field of dye-
sensitized solar cell (DSSC). The role of ruthenium complexes in DSSCs is to absorb sunlight 
and inject electrons into the conduction band of an electrode.45, 46 It has been shown that Ru(II) 
polypyridyl complexes perform very efficiently in DSSCs.47-53 The complexes used for DSSCs 
exhibit interesting photophysical properties, such as light absorption across the visible spectrum 
and long excited-state lifetimes. 54-57 These properties make this class of complexes highly 
interesting as potential PS in PDT. Hence, with the vast number Ru(II) polypyridyl complexes 
that have been investigated in the field of DSSC, we decided to probe this class of complexes as 
PSs in PDT. It would not be the first time that metal complexes designed for a specific purpose 
find a novel application in a completely unrelated field. For instance, compounds originally 
envisioned for catalysis are being found to be promising drug candidates, e.g. Hoveyda-Grubbs 
catalysts demonstrated antiproliferative activity against cancer cells similar to cisplatin.58, 59 We 
designed our novel, but representative complexes inspired by the work of Islam54, 55 and 
Abrahamson et al.56 For complex 1, we decided to use 4,7-1,10-diphenylphenanthroline (DIP) as 
the polypyridyl ligand since [Ru(DIP)3]2+ is a known PS with a high 1O2 yield (0.97 in MeOD).60 
Islam et al. reported that the absorbance of ruthenium complexes of the type (Ru(X)2(L), where 
X is a simple polypyridyl ligand, can be tuned by careful choice of L (two examples, 
Ru(dcbpy)(NCS)2 and Ru(dcbpy)(bdt) are shown in Fig. 1; dcbpy: 4,4′-dicarboxy-2,2′-
bipyridine, bdt: 1,2-benzenedithiol). For bidentate dithiol ligands in particular, extensive red-
shift of the complexes absorbance has reported. Based on these findings, we chose 1,2-
benzenedithiol (bdt) as the third ligand due to its structural simplicity. On the other hand, for 
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complex 2, we took into account the large body of research that indicated that tridentate 
polypyridyl ligands generally lead to broad absorption across the visible spectrum and perform 
inherently well in DSSC.57, 61-64 Also in this case, relatively simple ligands were used, with only 
one carboxylic acid functionality present. Herein we report the synthesis and characterization of 
two novel Ru(II) polypyridyl PS (1 and 2, Fig. 1), and their phototoxic activity against human 
cell lines and bacterial strains.  
 
 
Figure 1. Structures of two representative complexes Ru(dcbpy)(NCS)2 and Ru(dcbpy)(bdt) 
reported by Islam et al.54 and of the ruthenium polypyridyl complexes 1 and 2.  
 
Results and Discussion. 
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Synthesis and Characterization. The ruthenium(II) polypyridyl complex 1 was synthesized 
from [Ru(DIP)2Cl2] (1a), which was itself obtained from RuCl3 through a modified procedure 
reported by Caspar et al. (Scheme 1).65 Due to the rapid oxidation of the sulfido ligand upon 
contact with air a complex mixture of products was formed preventing the isolation of 1b. A 
similar observation was also reported by Begum et al.66 for a related ruthenium complex. 
Consequently, the mixture of differently oxidized species obtained from 1b was dissolved in 
acetonitrile and oxidized to the disulfinato complex 1 by addition of H2O2 and stirring at room 
temperature. After purification by column chromatography on silica, 1 could be obtained in 26% 
yield. The ligands, ptpy (ptpy = 4’-phenyl-2,2’:6’,2’’-terpyridine) and dqpCO2Me (dqpCO2Me = 
4-methylcarboxy-2,6-di(quinolin-8-yl)pyridine), were prepared according to literature 
procedures.67, 68 Starting from RuCl3, 2b was obtained and used without further purification for 
the next step. After column chromatography on silica and subsequent counterion exchange, 
complex 2 was obtained as a hexafluorophosphate salt in 47% yield. For 1, the only ESI-MS 
(positive mode) peak at 970.9 m/z could be assigned to be [M+H]+ (calculated: 971.1 m/z). For 2, 
the ESI-MS (positive mode) peak 401.0 m/z could be assigned to [M]2+ (calculated: 401.1 m/z). 
Furthermore, the presence of a single major peak in the UPLC analysis and the match of the 
elemental analysis with <0.3% deviation unambiguously confirmed the purity of 1 and 2. 
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Scheme 1. Reagents and conditions: (a) 4,7-diphenyl-1,10-phenanthroline, LiCl, DMF, 
overnight, reflux, 50 %; (b) 1,2-benzenedithiol, EtOH overnight, reflux; (c) 30% H2O2(aq), 
CH3CN, 30%, 48 h, r.t., 26%; (d) 4’-phenyl-2,2’:6’,2’’-terpyridine, EtOH 3 h, reflux; (e) i)  
AgBF4, acetone, 3 h, reflux; ii) 4-methylcarboxy-2,6-di(quinolin-8-yl)pyridine, butanol, 
overnight, reflux, 47 %. 
 
X-ray Crystal Structure. Single crystals of 2 were obtained by slow evaporation of a 
water/acetonitrile solution (1:1 v/v). Compound 2 crystallized in the orthorhombic space group 
Fdd2. The ORTEP representation, shown in Figure 2, reveals that while the ptpy ligand is almost 
planar, the dqpCO2Me ligand is strongly distorted out of the xy-plane. The Ru-N bond lengths 
and angles (see Table S1 in SI) are in good agreement with those for similar complexes reported 
in the literature.69, 70 
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Figure 2. ORTEP representation of 2. Ellipsoids are drawn at 20% probability level; Color code: 
carbon (grey), hydrogen (white). 
 
Photophysical Properties. In order to determine if complexes 1 and 2 have properties 
favorable for photosensitization, a series of photophysical measurements was performed. The 
UV/Vis absorption and photoluminescence spectra were measured in acetonitrile (Fig. S1 in SI). 
From the emission spectrum of 1, a luminescence quantum yield of 0.5% in acetonitrile could be 
calculated according to a standard procedure.71 Furthermore, the luminescence lifetime was 
determined in both air-equilibrated (λexc = 440 nm; 189 ± 4 ns) and degassed (λexc = 440 nm; 
1130 ± 28 ns) acetonitrile solutions. The results are comparable to those reported for similar 
Ru(II) polypyridyl complexes, indicating a phosphorescence-type emission.72 Luminescence 
lifetimes in the μs-range implicate a long-lived triplet excited state, which is thought to be 
important for efficient photosensitization.37 Altogether, complex 1 showed luminescence 
lifetimes favorable for photosensitization. The luminescence emission spectrum of 2 shows only 
weak intensity (Fig S1), which is reflected by a low emission quantum yield of <0.1%. The 
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luminescence lifetime was measured in toluene since it was below the detection limit when 
measured in acetonitrile. The lifetime was found to be 12 ± 2 ns under aerated conditions and 30 
± 1 ns in degassed toluene (λexc = 440 nm). These values are in agreement with those reported by 
Abrahamsson et al.56 for similar complexes, indicating a fluorescence-type emission. 
 
Stability in Human Plasma. In order to obtain a preliminary insight into the stability of 1 and 
2 under physiological conditions, they were incubated in human blood plasma at 37 °C, 
following our recently developed protocol.73, 74 No significant changes were observed either in 
the UV traces or in the ratio between diazepam (internal standard) and 1 and 2, respectively, 
even after 48 h (Fig. 3). These results suggest that 1 and 2 are stable under physiological 
conditions for a therapeutically relevant time. 
 
Figure 3. UV traces of UPLC analysis of 1 and 2 incubated in human plasma at 37 °C for 0 h, 
24 h and 48 h using diazepam as an internal standard. 
 
Singlet Oxygen Production. To assess the phototoxic potential of 1 and 2, their 1O2 
production quantum yields (ΦΔ) were determined in acetonitrile and phosphate buffered saline 
(PBS) by means of both an indirect and direct method as recently published by our group.75 For 
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both methods the complexes were irradiated with 420 nm light. In the first method, 1O2 
production is observed indirectly through the quenching of the absorbance at 420 nm 
(acetonitrile) or 440 nm (PBS) of N,N-dimethyl-4-nitrosoaniline (RNO) by a trans-annular 
peroxide adduct formed by the reaction of 1O2 with histidine in PBS. In acetonitrile, imidazole is 
used instead of histidine due to the low solubility of the latter in this solvent. By comparison of 
the quenching rates of our compounds with a reference compound (phenalenone at 420 nm) with 
a known 1O2 production rate76 at a given wavelength, the 1O2 quantum yield of 1 and 2 could be 
determined in acetonitrile and PBS at an irradiation wavelength of 420 nm. It is well 
acknowledged that the measurement of absorbance changes are not highly sensitive.77 To 
confirm the results obtained by the indirect assay, another method was employed. 1O2 displays a 
characteristic near-IR luminescence that can be observed at 1270 nm with an IR-sensitive 
detector. This method could only be applied for 1 since 2 did not show a sufficiently high signal-
to-noise ratio to obtain meaningful results. By comparison of the luminescence intensity 
measured for 1 with the one of phenalenone, a second set of 1O2 quantum yields could be 
obtained for this complex. The measured 1O2 quantum yields can be seen in Table 1. All values 
are expressed as the mean of three independent experiments with a standard deviation of less 
than 5%. Complex 1 showed an excellent 1O2 production (ΦΔ(1; ACN)indirect = 0.81; ΦΔ(1; 
ACN)direct = 0.92) in acetonitrile. In PBS, both measurement techniques, direct and indirect, were 
at the detection limit. It is well acknowledged that singlet oxygen in aqueous solution is short-
lived (≈3.5 µs) in comparison to acetonitrile (70-80 µs), which has a diminishing influence on 
the signal intensity.78 The low signal-to-noise ratio did not allow an estimation with the direct 
method whereas the indirect method led to a low quantum yield ΦΔ(1; PBS)indirect = 0.04). 
Complex 2 showed moderate 1O2 quantum yields at 420 nm in acetonitrile (ΦΔ(2; ACN)indirect = 
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0.15) but the direct measurement did not allow an evaluation of the quantum yield due to low 
signal-to-noise ratio. The different 1O2 quantum yields for 1 and 2 are probably related to the 
difference in their luminescence lifetimes. A long luminescence lifetime indicates a long-lived 
triplet-excited state, which in turn is favorable for photosensitization purposes.37 For both 
compounds, the highest 1O2 quantum yields were measured in the more lipophilic solvent 
acetonitrile. Since cells do not only have polar but also lipophilic environments, compounds 1 
and 2 could prove to be promising PSs.75  
 
Table 1. Singlet oxygen quantum yields of 1 and 2, values expressed as mean of three 
independent experiments (with standard deviation <5%). 
Compound Solvent 
Indirect Method 
ΦΔ(420 nm) 
Direct Method 
ΦΔ(420 nm) 
1 
ACN 
PBS 
0.81 
0.04 
0.92 
n.d.* 
2 
ACN 
PBS 
0.15 
0.03 
n.d.* 
n.d.* 
*not detected 
 
Cytotoxicity Studies. The cytotoxicity of 1 and 2 towards the human cervical cancer cell line 
(HeLa) was determined using a fluorometric cell viability assay (Resazurin). For comparison 
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purposes, the cytotoxicity of the compounds was also determined towards the human fibroblast 
(MRC-5) non-tumorigenic cell line with cisplatin as a reference. After 4 h incubation time, the 
medium was replaced with fresh medium (without complex) and the cells were irradiated at 
420 nm for 15 min. The corresponding light dose (6.95 J/cm2) is very similar to that used for the 
clinically approved PS porfimer sodium in comparable experiments (5 J/cm2).79 The IC50 values 
for all measurements are shown in Table 2. It must be noted that for the IC50 values determined 
without irradiation, two different values were obtained (for HeLa cells) for incubation times of 
48 h and 4 h, respectively. This was done to compare the values with cisplatin (48 h) and with 
the irradiation experiments (4 h). Complex 1 shows elevated cytotoxicity against both MRC-5 
and HeLa cell lines. Notably, the cytotoxicity is significantly higher against the tumorigenic cell 
line. Irradiation at 420 nm for 15 min increased the cytotoxicity of 1 to a remarkable IC50 value 
of 620 nM. This corresponds to a PI of 80 relative to the dark experiments. These results are 
even more interesting if compared to clinically established anticancer PDT agents. Under the 
same experimental conditions, 1 and 2 displayed a significantly higher phototoxicity and PI 
compared to another clinically approved PDT drug, namely 5-aminolevulinic acid (ALA),80-82 
which ist he precursor of protoporphyrin IX. Moreover, both the IC50 values and the PI of 1 
represent a significant improvement with respect to porfimer sodium. The latter was found to 
have an IC50 value of 2.57 ± 0.12 μg/ml and a corresponding PI of >10 upon 24 h incubation in 
HeLa cells and irradiation with the appropriate wavelenght and a comparable light dose (5 J/cm2) 
(IC50(dark): >25 μg/ml; cf. values in brackets in Table 2).79 Since cisplatin has a light-
independent mode of action, the PI is not applicable for this compound.83 Complex 2 displayed a 
very promising lack of activity towards non-tumorigenic cells (MRC-5) as well as towards 
cancerous cells (HeLa) in the dark in the range of concentrations measured in this study (up to 
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100 μM), while still demonstrating a moderate toxicity (IC50 = 25.3 ± 4.7 μM) upon irradiation 
and a PI of at least 4. The high phototoxicity observed for 1 upon irradiation at 420 nm is in 
agreement with the higher 1O2 quantum yields and stronger absorption observed at this 
wavelength. 
 
Table 2. IC50 values and phototoxic index (PI) for complexes 1 and 2, in HeLa cancer cells and 
MRC-5 non-tumorigenic cells with the IC50 values of cisplatin as a positive control. 
Compound 
MRC-5  
[μM (μg/ml)] 
(48 h, dark)a 
HeLa  
[μM (μg/ml)] 
(48 h, dark)a 
HeLa  
[μM (μg/ml)] 
(4 h, dark)b 
HeLa  
[μM (μg/ml)]  
(4 h, 420 nm)c 
PI 
1 
 15.6 ± 2.7 
(15.1 ± 2.6) 
5.7 ± 0.7 
(5.5 ± 0.7) 
49.7± 10.1 
(48.2 ± 9.8) 
0.62 ± 0.28 
(0.60 ± 0.27) 
80 
2 
>100 
(>100) 
>100 
(>100) 
>100 
(>100) 
25.3 ± 4.7 
(30.0 ± 5.6) 
>4 
ALAf >50 >50 >50  45.5 ± 3.2  >1 
Cisplatin 7.9 ± 1.2 11.5 ± 2.9 n.d.d 22.2 ± 5.7 n.a.e 
a48 h incubation at 37 °C, 6% CO2; b4 h incubation at 37 °C, 6% CO2; c4 h treatment 
followed by 15 min irradiation at 420 nm (6.95 J/cm2) and 44 h incubation at 37 °C, 6% CO2; 
dnot determined; enot applicable; f Measured IC50 values were adjusted taking into account that 
four molecules of ALA are required for the formation of one molecule of protoporphyrin IX, 
which represents the active species.84, 85 
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Cellular Localization. Having demonstrated that complex 1 possesses favorable photo-
luminescence and phototoxicity properties as well as being stable under physiological conditions, 
its cellular localization in HeLa cells was assessed by confocal microscopy. This cell line was 
selected since it is considered to be a reliable and economic model for human cervical cancer. 
Additionally, it is also a type of cancer that is accessible by fiber-optics, which is an essential 
requirement for PDT applications.86 Cells were stained with DAPI (Fig. 4a) and with the 
Mitotracker green FM (Fig. 4b). Complex 1 was visualized with an excitation at 400 nm (Fig. 
4c), which does not interfere with the other dyes. As can be seen in Fig. 4c, the luminescence of 
1 is highly visible. Fig. 4d shows the overlay of Fig 4a-4c. It can be observed that the area of the 
emission of 1 superimposes extremely well with the emission of the Mitotracker green FM, 
which localizes in mitochondria. Accumulation of the PS in the mitochondria is promising as 
they are important cell organelles and their damage can trigger different paths of cell death.73, 87 
We note that very poor photoluminescence of 2 precluded confocal microscopy studies. 
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Figure 4. Fluorescence confocal microscopy images of HeLa cells incubated with 40 μM of 1 
for 4 h: a) DAPI staining; b) Mitotracker green FM staining; c) visualization of 1 by excitation at 
405 nm. d) overlay of a-c. 
 
Cellular Uptake. Taking advantage of the presence of a metal in our systems, the 
accumulation of complexes 1 and 2 in cancer cells was investigated using inductively coupled 
plasma-mass spectrometry (ICP-MS). HeLa cells were incubated for different periods of time 
(0h, 4h and 48h) with the ruthenium compounds. 1 and 2 displayed a time dependent 
accumulation which is most pronounced for 1. 1 reached a 30% higher Ru content (35.0 ng/mg 
protein) than 2 (23.6 ng/mg protein) after 48 h. Although 1 and 2 demonstrated considerable to 
high phototoxicity, it has to be acknowledged that their cellular uptake into HeLa cells is quite 
moderate compared to other Ru(II) complexes.44, 88, 89  
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To obtain more detailed information about the localization of 1and 2their subcellular 
accumulation was investigated. Briefly, HeLa cells were incubated with 1 and 2 for 4 h and 
subsequently the nuclei and mitochondria of the cells were isolated while the remaining cell 
material was kept as a residual fraction. The two complexes displayed a quite different cellular 
distribution profile (Fig. 5). For 1, the results confirmed the data obtained by the microscopy 
studies with 67 % of the total Ru taken up by mitochondria (9.1 ± 1.3 ng/mg protein). We have 
previously observed a similarly high mitochondrial uptake with another class of Ru(II) 
polypyridyl complexes.73 In contrast to the microscopy results, a significant amount of Ru could 
also be observed in the nuclear fraction (28%, 3.8 ± 1.3). The residual cellular fraction contained 
only 5% of Ru (0.7 ± 0.3 ng/mg protein). For 2, the total ruthenium content of the isolated cell 
nuclei was 50 % of the total amount of up taken ruthenium (8.27 ± 0.27 ng/mg protein) while the 
mitochondria contained 29% (4.85 ± 0.42 ng/mg protein). The residual fraction contained 21% 
(3.44 ± 0.36 ng/mg protein). Taken together, these results indicate an overall moderate cellular 
uptake for both complexes 1 and 2. Nevertheless, both complexes displayed significant toxicity 
upon light irradiation (and also in the dark for 1) and chemical modifications (compounds (e.g. 
by coupling them to a targeting molecule) to improve their cellular uptake could further increase 
their phototoxicity. 
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Figure 5. Ruthenium uptake in the different cellular compartments of HeLa cells treated for 4 h 
with 20 μM of 2 and quantified by ICP-MS. 
 
Antibacterial Studies. To investigate the potential of complexes 1 and 2 as aPDT agents, their 
photoxicity was determined against two bacterial strains, the Gram-(+) S. aureus and the Gram-
(−) E. coli. The efficacy of a PS in aPDT can vary substantially depending on whether the 
bacterial strain is a Gram-(−) or Gram-(+) species, with Gram-(−) strains being less vulnerable to 
certain PS.90 The phototoxicity of 1 and 2 was determined according to a method recently 
published by Eichner et al.91 Briefly, solutions of each bacterial strain were incubated with the 
respective compound for 15 min at different PS concentrations. The cells were then irradiated for 
10 min with visible light (380-480 nm, λmax = 420 nm, 8 J/cm2) and the fraction of bacteria still 
alive was determined according to the Miles, Misra and Irwin method as the number of colony-
forming units (CFU) per ml.92 Control experiments were performed to exclude any additional 
toxicity by the solvent (DMSO) used to dissolve the complexes. The results are expressed as the 
mean of three independent experiments. In experiments where the bacteria were not irradiated, 
no significant change in CFU/ml was observed. For both 1 and 2, a reduction of > 6 log10 
(≥99.9999%) in cell viability was observed at concentrations of 50 μM (Figure 6) against the S. 
aureus strain. Considering the light dose of 8 J/cm2 and the short incubation time used in these 
experiments, the results are very promising, particularly with regard to those recently reported by 
Schastak et al.93 for a porphyrin PS. Complex 1 showed no detectable phototoxic effect against 
the E. coli strain while complex 2 reduced cell viability by > 4 log10 (≥99.99%) at 50 μM. This is 
interesting because Gram-(−) strains (like E. coli) are known to be less sensitive to certain types 
of PS. It has been reported that positively charged PS are more effective at killing Gram-(−) 
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bacteria and our findings are well in agreement with this hypothesis.90 Another series of Ru(II) 
polypyridyl complexes was tested against E. coli by Lei et al.94 In both cases, phototoxicty was 
observed but, since no light dose is reported, the results are not easily comparable. The decrease 
in cell viability against S. aureus is similar for 1 and 2, which is in contrast to the difference in 
IC50 values observed in the HeLa cell assay. This finding can be attributed to the 16-fold longer 
incubation time (15 min compared to 4 h) in the human cell experiments. Also, in contrast to the 
procedure with the human cells, the medium was not exchanged prior to the irradiation in these 
experiments, thereby possibly allowing the fraction of the compound that did not enter the 
bacteria to also damage the cells.  Both complexes showed high phototoxicity against the Gram-
(+) strain S. aureus and 2 also effectively reduced the cell viability of the Gram-(−) strain E. coli. 
This makes 1 and particularly 2 promising candidates for aPDT applications, where topical 
application and irradiation wavelengths in the 400-500 nm range can be used. 
 
Figure 6. Antibacterial activity of complexes 1 and 2 against the two bacterial strains, E. coli 
and S. aureus (conditions: 15 min treatment followed by 10 min irradiation at 420 nm (8 J/cm2) 
and 24 h incubation at 37 °C). 
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Conclusions 
In a first step to probe the large library of ruthenium compounds used in DSSC in the field of 
PDT, two novel ruthenium(II) polypyridyl complexes (1 and 2) have been prepared and 
characterized, including by X-ray crystallography for 2. Their stability in biological media, 
photophysical properties and 1O2 production quantum yields have been determined. Both 
complexes were shown to produce 1O2. Furthermore, their phototoxicity was evaluated against 
the human cervical cancer cell line HeLa. Complex 2 displayed phototoxicity in the low 
micromolar range against HeLa cells and, most importantly, no significant toxicity in dark 
experiments. Complex 1 showed phototoxicity in the nanomolar range with a PI of 80 against 
HeLa cells. This result is even more impressive when compared to the clinically approved PS 
ALA and porfimer sodium which display both lower phototoxicity and PIs in similar 
experimental settings.79 With the help of confocal microscopy experiments, 1 was shown to 
accumulate in the cytoplasm, particularly in mitochondria. These results were confirmed by ICP-
MS experiments, which showed an accumulation of around 67% of the total Ru taken up by the 
cell into the mitochondria. In comparison, the cellular uptake of 2 was shown to be quite more 
diffuse. In fact, 2 could be detected in all cellular compartments, with a slight preference for the 
cellular nucleus. Both complexes showed an overal cellular uptake 10-100 times lower than for 
other ruthenium complexes.44, 88, 89 Remarkably, 2 and particularly 1 still exhibited moderate to 
high toxicity upon light irradiation. Improving the cellular uptake of these compounds (e.g. by 
coupling them to a targeting molecule) could further increase both their toxicity and selectivity 
against cancer cells. 
 In the light of the novel up-and-coming field of aPDT, the phototoxicity of 1 and 2 was also 
tested against the two bacterial strains S. aureus and E. coli. The former effectively reduced cell 
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viability in the Gram-(+) strain S. aureus whereas no toxicity was observed against the Gram-(−) 
strain E. coli within the experimental conditions.  On the other hand, 2 effectively reduced cell 
viability in both, the Gram-(+) S. aureus and Gram-(−) E. coli, bacterial strains. The phototoxic 
profile of 2 against bacteria is particularly promising as Gram-(−) bacterial strains are reported to 
be inherently less affected by aPDT compared to Gram-(+) bacteria.90 Taken together, these 
results further emphasize the enormous potential of ruthenium complexes in PDT and also in the 
nascent field of aPDT. While the wavelength of irradiation used in this work is suitable for 
topical applications, further work will focus on the development of novel ruthenium PS that are 
active in the red-NIR region, where deeper tissue penetration can be achieved.  
 
Experimental section. 
Materials. All chemicals were of reagent grade quality or better, obtained from commercial 
suppliers and used without further purification. The Ligands dqpCO2Me and ptpy were prepared 
according to literature procedures.67, 68 The purity of all final compounds was shown to be 95% 
or higher by elemental microanalysis. Solvents were used as received or dried over molecular 
sieves. All preparations were carried out using standard Schlenk techniques. 
Instrumentation and Methods. 1H and 13C NMR spectra were recorded in deuterated solvents 
on 400 (1H: 400 MHz, 13C: 100.6 MHz) or 500 (1H: 500 MHz, 13C: 126 MHz) MHz 
spectrometers at room temperature. The chemical shifts, δ, are reported in ppm (parts per 
million). The residual solvent peaks have been used as an internal reference. The abbreviations 
for the peak multiplicities are as follows: s (singlet), d (doublet), dd (doublet of doublets), t 
(triplet), q (quartet), m (multiplet), and br (broad). ESI-MS and UPLC-MS were obtained with a 
Bruker Esquire 6000 mass spectrometer. LC-MS and UPLC-MS spectra were measured on an 
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AcquityTM from Waters system equipped with a PDA detector and an auto sampler using an 
ACQUITY UPLC BEH C18 Gravity 1.7 μm (2.1 × 50 mm) reverse phase column. A total of 2 μl 
of the solution was injected into the HPLC that was connected to a mass spectrometer operated 
in ESI mode The UPLC runs (flow rate: 0.6 ml/min) were performed with a linear gradient of A 
(acetonitrile (Sigma Aldrich HPLC-grade)) and B (distilled water containing 0.1% formic acid): t 
= 0−0.25 min, 5% A; t = 1.5 min, 100% A; t = 2.5 min, 100% A. Elemental microanalyses were 
performed on a LecoCHNS-932 elemental analyser. IR spectra were obtained with a Perkin 
Elmer Spectrum Two spectrometer. UV/Vis spectra were measured on a Varian Cary50Scan 
UV-Visible Spectrophotometer and Luminescence spectra on a Perkin Elmer LS 50 using 
fluorescence quartz cuvettes (width 1 cm).  
Synthesis.  
Ru(DIP)2Cl2: RuCl3 (110 mg, 0.42 mmol), 4,7-diphenyl-1,10-phenanthroline (DIP, 266 mg, 
0.8 mmol) and LiCl (100 mg, 2.36 mmol) were dissolved in DMF (10 ml). The mixture was 
heated to reflux overnight and then allowed to cool down to room temperature. Acetone (50 ml) 
was added to the solution to initialize recrystallization. The mixture was kept in the fridge for 
another day. The precipitate was collected by filtration and washed with diethylether (20 ml) and 
water (20 ml). The solid residue was dissolved in dichloromethane and collected. The solvent 
was removed in vacuo yielding a dark purple solid of Ru(DIP)2Cl2. Yield: 174 mg (50%). 
The analytical data matched that reported previously.65  
Ru(DIP)2(bdt) (1): Ru(DIP)2Cl2 (180 mg, 0.22 mmol) was dissolved in degassed EtOH (15 
ml). 1,2-dimercaptobenzene (94 mg, 0.66 mmol) was added and the solution heated to reflux 
under nitrogen atmosphere overnight. The solvent was evaporated to dryness. The dark solid was 
then dissolved in dichloromethane (30 ml) and extracted with 1M NaHCO3 (2x 20 ml). The 
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combined organic phases were dried over MgSO4 and the solvent removed on a rotary 
evaporator. The dry dark solid was dissolved in acetonitrile (30 ml). Aqueous H2O2 (1 ml, 30%) 
was then added to the mixture. The solution was stirred under nitrogen at room temperature for 
48 h. The solution was then cooled in an ice bath and MnO2 (1.0 g, 11.5 mmol) was added to the 
mixture. The mixture was left standing for 30 min before it was filtered (filter paper) multiple 
times to remove the insoluble MnO2. The remaining clear solution was evaporated to dryness. 
The resulting yellow solid was purified by column chromatography on silica (acetone/CH2Cl2 
4:1, Rf = 0.3). The product was obtained as an orange powder. Yield: 57 mg (26%). Anal. Calcd. 
for C54H36N4O4RuS2 (%): C, 66.86; H, 3.74; N, 5.78. Found: C, 67.02; H, 4.02; N, 5.59; IR 
bands (Golden Gate, cm-1): ν 1559, 1428, 1141, 1052, 1005, 829, 764, 735; 1H NMR (500 MHz, 
CD2Cl2): δ (ppm) 10.60 (d, 3J = 5.6 Hz, 2H), 8.15−8.12 (m, 4H), 8.04−8.01 (d, 2H), 7.83−7.80 
(m, 4H), 7.83−7.45 (m, 24H); 13C NMR (125 MHz, CD2Cl2): δ (ppm) 155.54, 153.54, 151.73, 
150.29, 150.14, 149.41, 148.45, 137.28, 137.00, 131.20, 130.90, 130.72, 130.33, 130.31, 130.00, 
129.85, 129.18, 128.76, 126.61, 126.34, 125.99, 125.83, 120.65; MS (ESI+): m/z 971.1 [M+H]+, 
993.3 [M+Na]+. HR-ESI mass spectrum (CH3CN + NaI): found 993.11267; calcd. for 
[C54H36N4NaO4RuS2] 993.11266; UV-Visible spectrum (CH3CN): λmax (εmax) = 396, 440(sh) nm 
(26300, 19200 M-1cm-1). 
Ru(dqpCO2Me)(ptpy) (2). A solution containing ptpy (0.15 g, 0.50 mmol) and RuCl3 (0.13 g, 
0.51 mmol) in absolute EtOH (50 mL) was heated to reflux for 3 h. The solid formed was 
isolated by filtration, washed with EtOH (10 ml) and Et2O (10 ml) and dried to yield the 
intermediate product, [Ru(ptpy)Cl3] as a red solid compound which was used directly in the next 
step of the synthesis. To 25 ml of acetone [Ru(ptpy)Cl3] (0.10 g, 0.21 mmol) and AgBF4 (0.14 g, 
0.70 mmol) were added and the mixture was refluxed for 3 h. After cooling to room temperature, 
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the mixture was filtered and the filtrate was evaporated to dryness on a rotary evaporator. To the 
residue dqpCO2Me (0.78 g, 0.21 mmol) and butanol (25 ml) were added. The mixture was 
heated to reflux overnight. After cooling to room temperature, 1 M aqueous KPF6 (2 ml) was 
added and half of the solvent evaporated on the rotary evaporator to precipitate the product, 
which was then collected by filtration. The obtained solid was subjected twice to flash column 
chromatography on silica gel (ACN: H2O: 1M NaNO3 18:1:1 v/v/v, Rf = 0.7). The darkest red 
band was collected and the solvent removed under reduced pressure. The residue was suspended 
in acetonitrile to dissolve the complex and to separate it from the insoluble NaNO3. After 
filtration, the ACN was removed on a rotary evaporator. The counterion was exchanged by 
addition of 1 M aqueous NH4PF6 (2 ml) and the precipitate was collected by filtration and 
washed with water. The product was dried in vacuo to yield the desired complex as a dark red 
powder. Yield: 110 mg, (47%). Anal. Calcd. for C46H32F12N6O2P2Ru.3 H2O.1 CH3CN (%): C, 
48.57; H, 3.48; N, 8.26. Found: C, 48.50; H, 3.46; N, 8.32; IR bands (neat, cm-1): ν 3060, 1718, 
1604, 1560, 1508, 1405, 1268, 1209, 1019, 845, 828; 1H NMR (400 MHz, CD3CN): δ (ppm) 
8.74 (dd, 3J = 7.7, 1.1, 2H), 8.72 (s, 2H), 8.61 (s, 2H), 8.35 (dd, 3J = 8.4, 7.6, 2H), 8.27 (d, 3J = 
7.3, 2H), 8.18 (dd, 3J = 8.1, 6.5, 2H), 8.04 (m, w = 11.2, 4H), 7.84 (m, w = 8.1, 4H), 7.68 (t, 3J = 
8.1, 1H), 7.60-7.65 (dd, 3J = 7.9, 2H), 7.30 (dd, 3J = 5.2, 1.4, 2H), 7.19 (m, w = 15.1, 2H), 6.98 
(dd, 3J =8.1, 5.2, 2H), 4.1 (s, 3H); 13C NMR (400 MHz, CD3CN): δ (ppm) 121.8, 124.1, 126.5, 
127, 127.5, 127.6, 127.7, 129.2, 130.3, 132.5, 132.9, 135.7, 135.9, 138, 138.1, 138.5, 145.6, 
148.6, 154.2, 154.5, 156.9, 157.4, 157.8, 52.8; ESI-MS (pos. detection mode): m/z: 401.1 [M]2+. 
UV-Visible spectrum (CH3CN): λmax (εmax) = 321, 362(sh), 460, 530, 570 nm (36700, 14800, 
10400, 8900, 7200, M-1 cm-1). 
Singlet Oxygen Production. 
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N,N-Dimethyl-4-nitrosoaniline/histidine assay. An air-saturated acetonitrile solution 
containing the complex (OD = 0.1 at irradiation wavelength), N,N-dimethyl-4-nitrosoaniline 
aniline (RNO) 24 μM, imidazole 12 mM or an air-saturated PBS buffer solution containing the 
complex (OD = 0.1 at irradiation wavelength), RNO 20 μM, histidine 10 mM were irradiated for 
different time intervals in a luminescence quartz cuvette at 420 nm in a RPR200 Rayonet 
Chamber Reactor (Southern New England Ultraviolet Company). The absorbance of RNO at 
440/420 nm was then plotted as a function of irradiation time and the quantum yields of singlet 
oxygen formation (Φsample) were calculated using phenalenone (for irradiation at 420 nm) as the 
standard (Φreference = 0.95) 76 with the formula: 
 
where S is the slope of the absorbance vs. irradiation time and I is the amount of light 
absorption calculated as the overlap of the lamp emission spectrum and absorption spectrum of 
the compound according to the following formula: 
 
where I0 is the light-flux intensity of the lamp and A is the absorbance of the compound. In 
control experiments, using the same experimental conditions, phenalenone was shown to be 
photostable for the relevant irradiation times. 
Near-IR Luminescence. Luminescence measurements were performed on a Fluorolog-3 
Spectrofluorometer (JobinYvon Horiba, Model FL3-11) fitted with a 450 W xenon lamp light 
source and single-grating excitation and emission spectrometers. For high beam intensity, the 
excitation slits were set to a maximum value of 29.4 nm. A colored glass filter was placed 
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between the sample and the detector to cut off light below 695 nm. The emission signal was 
collected at right angle to the excitation path with an IR-sensitive liquid nitrogen cooled 
germanium diode detector (Edinburgh Instruments, Model EI-L). The detector was bias at -
160V. The signal-to-noise ratio of the signal detected by the Ge-diode was improved with a lock-
in amplifier (Stanford Research Systems, model SR510) referenced to the chopper frequency of 
126 Hz. Data-acquisition was done with DataMax. In practice, a 20 mM stock solution of each 
compound dissolved in DMSO was diluted with PBS or acetonitrile (DMSO content of final 
solution <0.1%) to reach approximately an absorbance of 0.2 at the irradiation wavelength. This 
solution was then irradiated in fluorescence quartz cuvettes (width 1 cm) using a UV lamp (420 
nm, slit 29.4 nm). Singlet oxygen near-IR luminescence at 1271 nm was measured by recording 
spectra from 1200 to 1350 nm (emission slit 5 nm, detector sensitivity 100, integration 3 (1)). 
The intensity of irradiation was varied via neutral density filters. Singlet oxygen luminescence 
peaks at different irradiation intensities were integrated and the resulting areas were plotted vs. 
irradiation intensities. The quantum yields were calculated by applying the formulas as used for 
the N,N-dimethyl-4-nitrosoaniline/histidine assay with phenalenone as a reference.76 
Spectroscopic Studies. UV-Vis spectra were measured on a Varian Cary 50-Scan UV-Vis 
Spectrophotometer. To determine the luminescence quantum yields of the PSs, emission spectra 
were recorded on a Varian Cary Eclipse Fluorescence Spectrophotometer equipped with a 
Hamamatsu R3896 photomultiplier tube as detector, where the sample temperature can be 
controlled by a Peltier thermostatic system. Emission spectra were corrected for the spectral 
sensitivity of the detection system by standard correction curves. The emission intensities were 
normalized to a nominal absorption value of 0.1. Quantum yields in aerated acetonitrile were 
determined by comparison with the emission of [Ru(bipy)3]Cl2 in aerated water (Φ= 0.042).71 
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Luminescence lifetime measurements were recorded on an Edinburgh LP920 Laser Flash 
Photolysis transient absorption spectrometer using a flashlamp pumped Q-switched Nd:YAG 
laser (355 nm) as excitation source. 
Stability in Human Plasma. The stability of the compounds in human plasma at 37 °C was 
evaluated following a slightly modified procedure to that recently reported by our group.73, 74 
The human plasma was provided by the Blutspendezentrum, Zurich, Switzerland. Diazepam was 
obtained from Sigma Aldrich (internal standard). Stock solutions of the complexes (20 mM) and 
diazepam (3.2 mM) were prepared in DMSO. For a typical experiment, an aliquot of the 
respective stock solutions and DMSO were added to the plasma solution (975 μl) to a total 
volume of 1000 μl and final concentrations of 40 μM for the complexes and diazepam (final 
concentration of DMSO < 0.5%). The resulting plasma solution was incubated for either: 0, 24 or 
48 h at 37°C with continuous and gentle shaking (ca. 600 rpm). The reaction was stopped by 
addition of 2 ml of methanol, and the mixture was centrifuged for 45 min at 650 g at room 
temperature. The methanol solution was evaporated and the residue was suspended in 500 μl of 
1:1 (v/v) acetonitrile/H2O solution. The suspension was filtered and analyzed using UPLC−MS 
(as described in the instrumentation and methods part of this section).  
X-ray Crystallography. Single-crystal X-ray diffraction data were collected at 183(2) K on an 
Agilent Technologies SuperNova area-detector diffractometer using a single wavelength 
Enhance X-ray source with Cu K radiation (= 1.5418 Å)95 from a micro-focus X-ray source 
and an Oxford Instruments Cryojet XL cooler. The selected suitable single crystal was mounted 
using polybutene oil on a flexible loop fixed on a goniometer head and immediately transferred 
to the diffractometer. Pre-experiment, data collection, data reduction and analytical absorption 
correction96 were performed with the program suite CrysAlisPro.97 Using Olex2,98 the structure 
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was solved by the Superflip99 structure solution program using Charge Flipping and refined with 
the SHELXL2013100 program package by full-matrix least-squares minimization on F2. 
PLATON101 was used to check the result of the X-ray analysis. Crystal Data for 
C46H32F12N6RuP2O2 (M =1091.78): orthorhombic, space group Fdd2 (no. 43), a = 43.6636(10) 
Å, b = 43.3688(7) Å, c = 9.2311(2) Å, V = 17480.4(6) Å3, Z = 16, T = 182(2) K, μ(CuK) = 
4.489 mm-1, Dcalc = 1.659 g/mm3, 16177 reflections measured (5.744 ≤ 2Θ ≤ 136.418), 6703 
unique (Rint = 0.0275, Rsigma = 0.0308) which were used in all calculations. The final R1 was 
0.0782 (I > 2(I)) and wR2 was 0.2110 (all data). The supplementary crystallographic data for 
this paper has been deposited with the Cambridge Crystallographic Data Centre as CCDC-
990555. These data can be obtained free of charge from the Cambridge Crystallographic Data 
Centre via www.ccdc.cam.ac.uk/data_request/cif. 
Cell Culture. Human cervical carcinoma cells (HeLa) cells were maintained in DMEM 
(Gibco) with 5% fetal calf serum (FCS, Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin at 
37°C and 5% CO2. Normal lung fibroblasts (MRC-5) were cultured in F-10 medium (Gibco) 
supplemented with 10 % fetal calf serum (FCS, Gibco), 100 U/ml penicillin, 100 μg/ml 
streptomycin at 37°C and 5% CO2. 
Cytotoxicity Studies. Cytotoxicity studies of the effect of irradiation on human cervix HeLa 
cancer cell and MRC-5 non-tumorigenic cell lines treated with complexes 1 and 2 were 
performed by a fluorometric cell viability assay using Resazurin (Promocell GmbH). Briefly, one 
day before treatment cells were plated in triplicates in 96-well plates at a density of 4 × 103 cells 
/ well in 100 μL. Upon treating cells with increasing concentrations of the ruthenium complex 
(complex dissolved in DMSO, concentration of DMSO < 0.5%) cells were incubated for 4 h. The 
medium was then replaced by fresh medium, which does not contain complexes 1 and 2 and the 
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plates were irradiated for 15 minutes at 420 nm (6.95 J/cm2) or at 575 nm (6.23 J/cm2) in a 
RPR200 Rayonet Chamber Reactor (Southern New England Ultraviolet Company). Upon further 
incubation at 37°C / 6% CO2 for 44 h, the medium was removed, and 100 μL of complete 
medium containing resazurin (0.2 mg/ml final concentration) was added. After 4 h of incubation 
at 37 °C / 6% CO2, the fluorescence of the highly red fluorescent resorufin product was 
quantified at 590 nm emission with 540 nm excitation wavelength in a SpectraMax M5 
microplate Reader. 
Microscopy Studies. 
In Vitro Fluorescence Evaluation. Cellular localization of 1 was performed by fluorescence 
microscopy. HeLa cells were grown on 18 mm M enzel-Gläser coverslips in 2 ml complete 
medium at a density of 2.5 × 105 cells/ml and incubated for 2 h with 1 at 40μM (DMSO 
concentration < 0.5%). Cells were fixed in 4% formaldehyde solution (10% formaldehyde in 
90% PBS) and mounted on slides for viewing by confocal microscopy on a CLSM Leica SP5 
microscope. The ruthenium complex was excited at 456 nm and emission above 610 nm was 
recorded. 
Nuclear and Mitochondrial Staining. Co-localization of complex 1 into the nucleus and 
mitochondria was examined by means of Mito-tracker green FM (Molecular Probes, excitation: 
490 nm, emission: 516 nm), a mitochondria-specific dye and DAPI (excitation: 358 nm, 
emission: 461 nm). Briefly, a 1 mM Mitotracker Green FM stock solution made in DMSO was 
diluted to 10 μM working concentration in cell medium (DMEM, 5% FCS). Staining of 
mitochondria was accomplished by adding a 50 nM final concentration of Mito-tracker Green 
FM to the culture medium for the last 45 min incubation. The medium was removed and cells 
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were fixed in 4% formaldehyde solution before being mounted on slides added with 8 μl of 
DAPI (Invitrogen) for viewing by confocal microscope. 
Uptake Studies. 
Sample Preparation for ICP-MS.  
Whole Cells. HeLa cells were seeded two days before treatment at a concentration of 1x106 
cells/ml in 25 cm2 cell culture flask till 80% of confluence and incubated with the target 
complexes at 20 μM for 0, 4 and 48 hours (DMSO concentration < 0.1%). The medium was 
removed, the cells washed with PBS and trypsinized. After re- suspension in PBS, the pellet was 
collected by centrifugation at 5500 rpm for 4.5 minutes. Pellets were redissolved in 500 μL of 
PBS, lysed by a freeze-thaw cycle and treated on ultrasonic bath for 20 minutes (Digitana AG). 
The lysates were lyophilized on an Alpha 2-4 LD plus (CHRIST).  
Cellular Fractions. HeLa cells were seeded two days before treatment at a concentration of 
1x106 cells/ml in 175 cm2 cell culture flask till 80% of confluence and incubated with the target 
complexes at 20 μM for 4 hours (DMSO concentration < 0.1%). The medium was removed, the 
cells washed with PBS and trypsinized. After re-suspension in PBS, the pellet was collected per 
centrifugation (5910R, Eppendorf) at 500 g for 5 min at 4 °C. Mitochondria were isolated using 
a mitochondria isolation kit (Cat. Nr.: MITISO2, Sigma Aldrich) following the producer 
instructions. Briefly, the collected pellets were redissolved in 1.5 ml of lysis buffer (delivered 
with the kit) and allowed to react for 15 min on ice. The samples were homogenized with a pre-
chilled dounce homogenizer (7 ml, tight pestle A, 30 strokes) and centrifuged at 600 g for 10 min 
at 4 °C. The supernatant was transferred in a fresh tube and centrifuged at 11000 g for 10 min at 
4 °C. The obtained pellets represented pure mitochondrial fractions. For nucleus isolation nuclei 
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of HeLa cells were obtained following an established procedure with minor modifications.102 All 
the fractions were isolated from the same cellular sample for direct comparative purposes. After 
homogenization, the pellet obtained was redissolved in 2 ml of a sucrose solution (0.25 M 
sucrose, 10 mM MgCl2) and layered with 3 ml of a second hypertonic sucrose solution (0.35 M 
sucrose, 0.5 mM MgCl2). The suspension was centrifuged at 1450 g and 4 °C for 5 min. The 
pellet was re-suspended in 3 ml of the second sucrose solution and centrifuged at 1450 g and 4 
°C for 5 min to obtain the pure nuclear extract. All the steps of the isolation procedure were 
monitored under phase contrast microscope on Menzel-Gläser coverslips (Olympus IX81 
microscope). The supernatant phases discarded during the isolation of nuclei and mitochondria 
procedures were collected and formed the rest fraction. An aliquot of crude lysate supernatant, 
nuclear, mitochondrial and rest fraction was each used for protein quantification using the 
Bradford method.103 The isolated samples were lyophilized on an Alpha 2-4 LD plus (CHRIST). 
ICP-MS Studies. ICP-MS measurements were performed on an Agilent QQQ 8800 Triple 
quad ICP-MS spectrometer (Agilent Technologies) with a ASX200 autosampler (Agilent 
Technologies), equipped with standard nickel cones and a “micro-mist” quartz nebulizer fed with 
0.3 ml/min analytic flow (as a 2% HNO3 aqueous solution). Ruthenium was measured against a 
Ru single element standard (Merck 170347) and verified by a control (Agilent5188-6524 PA 
Tuning 2). Ruthenium content of the samples was determined by means of a 7-step serial dilution 
in the range between 0 and 100 ppb in Ru (R=1.0) with a background equivalent concentration of 
BEC: 3.3 ppt and a detection limit of DL: 5.4 ppt. The isotope 101Ru (17.06% abundance) was 
evaluated in “no-gas” mode. Spiking the samples with 1% methanol (to account for eventual 
carbon content from the biological samples) resulted in equivalent values within error ranges. 
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The results are expressed as ng Ru / mg protein (correction due to the different mass of the 
observed cellular compartments), as mean ± error of different independent experiments. 
Bacteria Culture and Phototoxicity. An overnight bacteria culture (5 ml) was harvested by 
centrifugation (200 g, 15 min), washed with 0.01 mM phosphate-buffered saline (PBS; 
Biochrom, Berlin, Germany) at pH 7.4 containing 0.027 mol/l KCl and 0.14 mol/l NaCl, and 
suspended in PBS at an optical density of 0.6 at 600 nm, which corresponded to ~108 bacteria 
ml-1, for use in the phototoxicity experiments. The bacterial suspensions were incubated with the 
respective PS and then irradiated using an incoherent light source (UV236, kem: 380–480 nm; 
max 420 nm; Waldmann Medizintechnik, Villingen-Schwenningen, Germany). To minimize 
scattering, the 96 -well plates were exposed to the PS-bacteria suspension from the bottom of the 
plates. 100 µl of a bacterial suspension (S. aureus (atcc 25923) or E. coli (atcc 25922)) with a 
concentration of ≈ 108 bacteria per ml were incubated in a 96 -well plate with different PS 
concentrations (each 100 µl) for 15 min at room temperature under exclusion of light.  
Immediately thereafter, the bacteria were irradiated with a total light dose of 8 J/cm2 (time 
period: 10 min). Control samples were either incubated with PS only or irradiated only without 
any PS incubation. After irradiation, the surviving bacteria were determined by plating out and 
enumeration of the colony forming units (CFU per ml). Therefore, serially diluted aliquots of 
treated and untreated cells were plated on Müller-Hinton agar and the number of CFU per ml 
was counted after 24 h at 37 °C. The method used to determine the growth of bacteria was 
originally described by Miles, Mirsa & Irwin.92 A Müller-Hinton agar plate was divided into six 
quadrants and three drops of 20 µl each per quadrants were applied of the serially diluted 
suspensions. After each three drops, the pipette tips were changed. After the droplets were dried, 
the agar plates were inverted and incubated at 37 °C for 24 h. The day after the surviving 
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colonies were counted, and the three values of the respective dilution steps were summed up and 
an average value was calculated. A reduction of at least three orders of magnitude (i.e., 3 log10 
units) of viable mean numbers of bacteria was stated as biologically relevant with regard to the 
guidelines of hand hygiene.104  
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DIP: 4,7-diphenyl-1,10-phenanthroline, bdt: 1,2-benzenedi-thiolate, dqpCO2Me:  4-
methylcarboxy-2,6-di(quinolin-8-yl)pyridine), ptpy = 4’-phenyl-2,2’:6’,2’’-terpyridine, PS: 
photosensitizer, PDT: photodynamic therapy, ICP-MS: inductively coupled plasma-mass 
spectrometry, ROS: reactive oxygen species, aPDT: antimicrobial PDT, PI: phototoxic index, 
RNO: N-dimethyl-4-nitrosoaniline, ACN: acetonitrile, CFU: colony-forming unit. 
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